Cardiorenal benefits of early versus late cyclosporine to sirolimus conversion in a rat model

Journal of Pharmacology and Pharmacotherapeutics

Volumn 3, Issue 2, 2012, Pages 143-148

  Sereno, José ^a   Romão, Ana M ^a   Parada, Belmiro ^a,b   Lopes, Patrícia ^c   Carvalho, Eugénia ^c   Teixeira, Frederico ^a   Reis, Flávio ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

cardiotoxicity; Cyclosporine; early versus late conversion; nephrotoxicity; sirolimus

Indexed keywords

CREATINE KINASE; CYCLOSPORIN A; GLUCOSE; RAPAMYCIN; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE MEASUREMENT; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART MUSCLE METABOLISM; HEART RATE; HYPERTENSION; KIDNEY METABOLISM; LIPID PEROXIDATION; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; RAT; TACHYCARDIA;

EID: 84878801249     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.95513     Document Type: Article

References (41)

1. Cattaneo D, Perico N, Gaspari F, Remuzzi G. Nephrotoxic aspects of cyclosporine. Transplant Proc 2004;36:S234-9
2. Textor SC, Taler SJ, Canzanello VJ, Schwartz L, Augustine JE. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl 2000;6:521-30
3. Zeier M, Dikow R, Ritz E. Blood pressure after renal transplantation. Ann Transplant 2001;6:21-4
4. Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA 2000;283:633-8
5. Reis F. The unsolved cyclosporine-induced kidney injury: Isparicalcitol a feasible new renoprotective option? Kidney Int 2010;77:1055-7
6. Małyszko J, Małyszko JS, Takada A, Myśliwiec M. Effects of immunosuppressive drugs on platelet aggregation in vitro. Ann Transplant 2002;7:55-68
7. Reis F, Tavares P, Fontes Ribeiro CA, Antunes F, Teixeira F. The peripheral serotonergic system and platelet aggregation in cyclosporin A-induced hypertensive rats. Thromb Res 1999;96:365-72
8. Reis F, Tavares P, Rito LC, Teixeira HM, Santos Dias JD, Ferrer-Antunes C, et al. Platelet activation is increased in cyclosporin A-induced hypertensive rats. J Cardiovasc Pharmacol 2000;36:56-64
9. Reis F, Tavares P, Teixeira F. The distribution of catecholamines between plasma and platelets in cyclosporin A-induced hypertensive rats. Pharmacol Res 2000;41:129-35
10. Reis F, Almeida L, Alcobia T, Santos-Dias JD, Lourenço M, Palmeiro A, et al. Isosorbide-5-mononitrate treatment prevents cyclosporin A-induced platelet hyperactivation and the underlying nitric oxide-cyclic guanosine-3',5'-mono-phosphate disturbances. Thromb Res 2003;110:107-15
11. Reis F, Ponte L, Rocha L, Teixeira-Lemos E, Almeida L, Alcobia T, et al. Curative isosorbide-5-mononitrate treatment, in opposition to the beneficial preventive one, aggravates the prothrombotic and proconstrictor state in cyclosporin-induced hypertensive rats. Clin Exp Pharmacol Physiol 2005;32:640-8
12. Reis F, Rocha L, Ponte L, Alcobia T, Almeida L, Costa-Almeida C, et al. Effect of preventive and regressive isosorbide 5-mononitrate treatment on catecholamine levels in plasma, platelets, adrenals, left ventricle and aorta in cyclosporin A-induced hypertensive rats. Life Sci 2005;77:2514-28
13. Reis F, Teixeira de Lemos E, Almeida L, Parada B, Garrido AP, Rocha-Pereira P, et al. Dual effect of nitrate therapy for cyclosporin-induced hypertension on vascular and platelet morphofunctional markers. Transplant Proc 2007;39:2501-6
14. Reis F, Rocha-Pereira P, Teixeira de Lemos E, Parada B, Baptista S, Figueiredo A, et al. Oxidative stress in cyclosporin-induced hypertension: Evidence of beneficial effects or tolerance development with nitrate therapy. Transplant Proc 2007;39:2494-500
15. Parada B, Mota A, Nunes P, Macário F, Pratas J, Bastos C, et al. Calcineurin inhibitor-free immunosuppression in renal transplantation. Transplant Proc 2005;37:2759-61
16. Hakeam HA, Al-Jedai AH, Raza SM, Hamawi K. Sirolimus induced dyslipidemia in tacrolimus based vs.tacrolimus free immunosuppressive regimens in renal transplant recipients. Ann Transplant 2008;13:46-53
17. Mota A. Sirolimus: A new option in transplantation. Expert Opin Pharmacother 2005;6:479-87
18. Reis F, Parada B, Lemos E, Garrido P, Dias A, Piloto N, et al. Hypertension induced by immunosuppressive drugs-comparative analysis between Sir and CsA. Transplant Proc 2009;41:868-73
19. Merkel S, Mogilevskaja N, Mengel M, Haller H, Schwarz A. Side effects of sirolimus. Transplant Proc 2006;38:714-5
20. Jensen GS, Wiseman A, Trotter JF. Sirolimus conversion for renal preservation in liver transplantation: Not so fast. Liver Transpl 2008;14:601-3
21. DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl 2008;14:651-9
22. Boratyńska M, Banńasik M, Watorek E, Falkiewicz K, Patrzałek D, Szyber P, et al. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 2006;38:101-4
23. Rangan GK. Sirolimus-Associated proteinuria and renal dysfunction. Drug Saf 2006;29:1153-61
24. Estepa V, Ródenas S, Martín MC. Optimización de un método para la determinaci ón de la peroxidación lipídica en suero humano. Anales de la Real Academia de Farmacia 2001;67:1-17
25. Rogers CC, Johnson SR, Mandelbrot DA, Pavlakis M, Horwedel T, Karp SJ, et al. Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients. Clin Transplant 2009;23:887-96
26. Maharaj S, Assounga AG. Conversion of cyclosporine to sirolimus before 12 months is associated with marked improvement in renal function and low proteinuria in a South African renal transplant population. Exp Clin Transplant 2010;8:14-8
27. Moro J, Almenar L, Martínez-Dolz L, Agüero J, Rueda J, Arnau MA, et al.mTOR inhibitors: Do they help preserve renal function? Transplant Proc 2007;39:2135-7
28. Marti HP, Frey FJ. Nephrotoxicity of rapamycin: An emerging problem in clinical medicine. Nephrol Dial Transplant 2005;20:13-5
29. Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, et al. Long-Term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005;20:2517-23
30. Pallet N, Thervet E, Le Corre D, Knebelmann B, Nusbaum P, Tomkiewicz C, et al. Rapamycin inhibits human renal epithelial cell proliferation: Effect on cyclin D3 mRNA expression and stability. Kidney Int 2005;67:2422-33
31. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence. Transplantation 2006;82:1153-62
32. Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: Benefits and risks. Nephrol Dial Transplant 2006;21:562-8
33. Laham G, Sleiman S, Soler Pujol G, Diaz C, Dávalos M, Vilches A. Conversion to sirolimus allowspreservation of renal function in kidney and kidney-pancreas allograft recipients. Transplant Proc 2010;42:309-13
34. Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease. J Heart Lung Transplant 2009;28:564-71
35. He Z, Chen L, Qiu J, Li J, Zhao D, Chen G, et al. Conversion from cyclosporine A to sirolimus retards the progression of chronic allograft nephropathy in the long term in a rat kidney transplantation model. J Int Med Res 2009;37:1396-410
36. Zeier M, Van Der Giet M. Calcineurin inhibitor sparing regimens using m-Target of rapamycin inhibitors: An opportunity to improve cardiovascular risk following kidney transplantation? Transpl Int 2011;24:30-42
37. Rovira J, Arellano EM, Carreras J, Campos B, Vodenik B, Bañón-Maneus E, et al. Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction. Transplantation 2009;88:646-52
38. Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C. The mTOR inhibitor everolimus inducesproteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007;84:1492-9
39. Fernandes I, Zhang Y, Qi Y, Wang ME, Podder H, Lisik W, et al. Impact of reduced nephron mass on cyclosporine-And/or sirolimus-induced nephrotoxicity. Transplantation 2009;88:1323-31
40. Cai Y, Chen Y, Zheng S, Chen B, Yang Y, Xia P. Sirolimus damagespodocytes in rats with protein overload nephropathy. J Nephrol 2011;24:307-12
41. Song HK, Han DH, Song JH, Ghee JY, Piao SG, Kim SH, et al. Influence of sirolimus on cyclosporine-induced pancreas islet dysfunction in rats. Am J Transplant 2009;9:2024-33